Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randall L Morrison

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Scientific Reports|October 31, 2023
Personalized relapse prediction in patients with major depressive disorder using digital biomarkersSrinivasan Vairavan, Homa Rashidisabet, Qingqin S Li, et al.
The International Journal of Neuropsychopharmacology|May 4, 2025
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension studyNaim Zaki, Li Nancy Chen, Rosanne Lane, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 18, 2019
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3Rachel Ochs-Ross, Ella J Daly, Yun Zhang, et al.
The Journal of Clinical Psychiatry|April 22, 2020
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)Ewa Wajs, Leah Aluisio, Richard Holder, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Scientific Reports|October 31, 2023
Personalized relapse prediction in patients with major depressive disorder using digital biomarkersSrinivasan Vairavan, Homa Rashidisabet, Qingqin S Li, et al.
The International Journal of Neuropsychopharmacology|May 4, 2025
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension studyNaim Zaki, Li Nancy Chen, Rosanne Lane, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 18, 2019
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3Rachel Ochs-Ross, Ella J Daly, Yun Zhang, et al.
The Journal of Clinical Psychiatry|April 22, 2020
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)Ewa Wajs, Leah Aluisio, Richard Holder, et al.
Pageof 2